We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

112 hedge funds and large institutions have $81.8M invested in Lyell Immunopharma in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 36 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

7% more funds holding

Funds holding: 105 → 112 (+7)

0.01% more ownership

Funds ownership: 2.57% → 2.58% (+0.01%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

15% less capital invested

Capital invested by funds: $95.9M → $81.8M (-$14.1M)

33% less call options, than puts

Call options by funds: $2K | Put options by funds: $3K

36% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 36

Holders
112
Holders Change
+7
Holders Change %
+6.67%
% of All Funds
1.5%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
14
Increased
23
Reduced
36
Closed
7
Calls
$2K
Puts
$3K
Net Calls
-$1K
Net Calls Change
-$2K

Top Buyers

1
FCMI
Foresite Capital Management IV
California
+$4.71M
2
AC
Almitas Capital
California
+$877K
3
Citadel Advisors
Citadel Advisors
Florida
+$461K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$272K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$160K

Top Sellers

1
O
OrbiMed
New York
-$1.99M
2
Millennium Management
Millennium Management
New York
-$560K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$545K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$506K
5
UBS Group
UBS Group
Switzerland
-$462K
Name Holding Trade Value Shares
Change 		Change in
Stake
SO
101
STRS Ohio
Ohio
$2.74K – – –
VWA
102
VSM Wealth Advisory
Maryland
$2.69K +$3.06K +250 New
SCM
103
Sterling Capital Management
North Carolina
$1.55K -$1.58K -129 -47%
MCM
104
MAI Capital Management
Ohio
$1.08K – – –
CCM
105
Coldstream Capital Management
Washington
$628 +$711 +58 New
US Bancorp
106
US Bancorp
Minnesota
$627 – – –
PNC Financial Services Group
107
PNC Financial Services Group
Pennsylvania
$549 +$625 +51 New
Nisa Investment Advisors
108
Nisa Investment Advisors
Missouri
$269 -$110 -9 -26%
EWA
109
EverSource Wealth Advisors
Alabama
$57 +$61 +5 New
TWD
110
True Wealth Design
Ohio
$33 +$37 +3 New
O
111
OrbiMed
New York
– -$1.99M -155,181 Closed
RL
112
RPO LLC
Connecticut
– -$42.5K -3,319 Closed
Ameriprise
113
Ameriprise
Minnesota
– -$24K -1,874 Closed
JFG
114
Jefferies Financial Group
New York
– -$10.4K -816 Closed
EBA
115
Eagle Bay Advisors
New York
– -$7.17K -560 Closed
Simplex Trading
116
Simplex Trading
Illinois
– +$233 +19 +61%
1 2 3 4
5

LYEL Hedge Fund Activity: Q1 2025 in Review

112 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q1 2025, worth a combined $81.8M — down 15% from $95.9M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new LYEL positions and 7 closed out — a net gain of 7 holders — while 23 added to existing stakes and 36 trimmed.

The largest buyer was Foresite Capital Management IV, adding an estimated $4.71M. The largest seller was OrbiMed, exiting entirely with an estimated $1.99M sold.

  • 112 institutional investors held Lyell Immunopharma (LYEL) as of Q1 2025, up from 105 in Q4 2024.
  • Funds reported $81.8M of Lyell Immunopharma stock for Q1 2025, down 15% quarter-over-quarter.
  • 14 funds opened new Lyell Immunopharma positions in Q1 2025 and 7 closed out, a net change of +7 holders.
  • The largest Lyell Immunopharma buyer in Q1 2025 was Foresite Capital Management IV, an estimated $4.71M added.
  • The largest Lyell Immunopharma seller in Q1 2025 was OrbiMed, an estimated $1.99M sold.

Based on aggregated 13F filings for Q1 2025.